FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Popovits Kimberly J 2. Date of Event Requiring Statement (MM/DD/YYYY)
2/11/2021 

3. Issuer Name and Ticker or Trading Symbol Talis Biomedical Corp [TLIS]
(Last)       (First)       (Middle)
C/O TALIS BIOMEDICAL CORPORATION, 230 CONSTITUTION DRIVE
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                          _____ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)
MENLO PARK, CA 94025      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
2/11/2021 

6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series E-1 Preferred Stock   (1)  (1) Common Stock  0   (1) I  See footnote (1)

Explanation of Responses:
(1)  300,000 shares of Series E-1 preferred shares reported in the originally filed Form 3 were mistakenly identified as held by the Reporting Person's spouse. These shares are held by a non-affiliate relative of the Reporting Person. The subsequent Form 4 filed by the Reporting Person also erroneously included these indirect holdings. This Form 3/A is being filed to correct the aforementioned error.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Popovits Kimberly J
C/O TALIS BIOMEDICAL CORPORATION
230 CONSTITUTION DRIVE
MENLO PARK, CA 94025
X



Signatures
/s/ Karen E. Flick, Attorney-in-Fact for Kimberly J. Popovits 4/5/2021
**Signature of Reporting Person Date
Talis Biomedical (NASDAQ:TLIS)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Talis Biomedical Charts.
Talis Biomedical (NASDAQ:TLIS)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Talis Biomedical Charts.